BIOMARKER:

PD-L1 expression + EGFR mutation

Entrez ID:

Related biomarkers:

‹

›

PD-L1 expression + EGFR mutation PD-L1 expression + EGFR mutation	Non Small Cell Lung Cancer NSCLC	PD-L1 expression + EGFR mutation PD-L1 expression + EGFR mutation	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: C4 – Case Studies J Oncol Pharm Pract - 2 weeks	pembrolizumab Sensitive: C4 – Case Studies J Oncol Pharm Pract - 2 weeks
PD-L1 expression + EGFR mutation PD-L1 expression + EGFR mutation	Non Small Cell Lung Cancer NSCLC	PD-L1 expression + EGFR mutation PD-L1 expression + EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR inhibitor Resistant: C3 – Early Trials	EGFR inhibitor Resistant: C3 – Early Trials
PD-L1 expression + EGFR mutation PD-L1 expression + EGFR mutation	Non Small Cell Lung Cancer NSCLC	PD-L1 expression + EGFR mutation PD-L1 expression + EGFR mutation	Non Small Cell Lung Cancer NSCLC	PD-L1 inhibitor Resistant: C3 – Early Trials	PD-L1 inhibitor Resistant: C3 – Early Trials